13F portfolio / Healthcare and biotechnology
RA Capital
Peter Kolchinsky · Rajeev Shah (managing partners)
RA Capital Management is a Boston investment firm.
It makes public and private investments in healthcare, biotechnology and planetary health.
The firm is based in Boston, MA, according to its SEC filings.
Its earliest 13F holdings report on SEC EDGAR was filed in February 2008.
- Reported 13F value
- $11.5B
- Positions
- 84
- Est. 1-yearEstimate
- —SPY +15.7%
- Est. 3-year, annualizedEstimate
- —SPY +22.8%
As of Jun 30, 2026 · filed Aug 14, 2026
Holdings
17 new · 9 added · 10 trimmed · 48 unchanged · 18 sold out
| 1 | ASND on Yahoo Finance (opens in a new tab) | Ascendis Pharma A/SCommon Stock | 23.8% | $2.7B | 10,281,496 | New | $233.60 | $225.73 | -3.4% |
| 2 | PBLS on Yahoo Finance (opens in a new tab) | Parabilis Medicines IncCommon Stock | 6.9% | $792M | 28,933,371 | New | $27.62 | $23.77 | -13.9% |
| 3 | RYTM on Yahoo Finance (opens in a new tab) | Rhythm Pharmaceuticals IncCommon Stock | 6.4% | $740M | 6,666,837 | Unchanged | $39.40* | $86.58 | +119.7% |
| 4 | PCVX on Yahoo Finance (opens in a new tab) | Vaxcyte IncCommon Stock | 5.8% | $667M | 11,474,599 | Unchanged | $61.05* | $62.76 | +2.8% |
| 5 | SION on Yahoo Finance (opens in a new tab) | Sionna Therapeutics IncCommon Stock | 3.8% | $436M | 9,905,045 | Unchanged | $16.34 | $3.88 | -76.3% |
| 6 | TYRA on Yahoo Finance (opens in a new tab) | Tyra Biosciences IncCommon Stock | 3.4% | $390M | 12,198,625 | Unchanged | $14.37* | $18.47 | +28.5% |
| 7 | EWTX on Yahoo Finance (opens in a new tab) | Edgewise Therapeutics IncCommon Stock | 3.0% | $341M | 8,392,730 | Trimmed -19.5% | $15.67 | $36.90 | +135.5% |
| 8 | NAMS on Yahoo Finance (opens in a new tab) | Newamsterdam Pharma Co NVCommon Stock | 2.8% | $324M | 9,550,191 | Unchanged | $12.49* | $20.05 | +60.6% |
| 9 | COAG on Yahoo Finance (opens in a new tab) | Hemab Therapeutics HoldingsCommon Stock | 2.5% | $287M | 7,808,627 | New | $27.59 | $30.25 | +9.6% |
| 10 | SEPN on Yahoo Finance (opens in a new tab) | Septerna IncCommon Stock | 2.0% | $234M | 6,995,858 | Unchanged | $23.65 | $36.09 | +52.6% |
| 11 | BCAX on Yahoo Finance (opens in a new tab) | Bicara Therapeutics IncCommon Stock | 1.9% | $215M | 7,255,993 | Unchanged | $25.16 | $16.92 | -32.7% |
| 12 | MLYS on Yahoo Finance (opens in a new tab) | Mineralys Therapeutics IncCommon Stock | 1.8% | $208M | 7,692,750 | Unchanged | $13.93* | $20.20 | +45.0% |
| 13 | GHRS on Yahoo Finance (opens in a new tab) | Gh Research PLCCommon Stock | 1.8% | $205M | 7,636,813 | Trimmed -0.5% | $10.23* | $18.08 | +76.8% |
| 14 | IRON on Yahoo Finance (opens in a new tab) | Disc Medicine IncCommon Stock | 1.6% | $179M | 2,450,221 | Unchanged | $62.98 | $56.21 | -10.7% |
| 15 | SGP on Yahoo Finance (opens in a new tab) | Spyglass Pharma IncCommon Stock | 1.6% | $179M | 8,021,117 | Unchanged | $26.90 | $24.58 | -8.6% |
| 16 | ARTV on Yahoo Finance (opens in a new tab) | Artiva Biotherapeutics IncCommon Stock | 1.5% | $174M | 17,955,642 | Added +82.2% | $10.47 | $5.94 | -43.3% |
| 17 | JANX on Yahoo Finance (opens in a new tab) | Janux Therapeutics IncCommon Stock | 1.5% | $172M | 11,189,693 | Unchanged | $16.75* | $16.76 | +0.1% |
| 18 | TSHA on Yahoo Finance (opens in a new tab) | Taysha Gene Therapies IncCommon Stock | 1.4% | $160M | 23,555,648 | Unchanged | $2.67* | $3.63 | +36.1% |
| 19 | BCRX on Yahoo Finance (opens in a new tab) | Biocryst Pharmaceuticals IncCommon Stock | 1.4% | $158M | 15,827,186 | Unchanged | $7.23 | $7.78 | +7.5% |
| 20 | WVE on Yahoo Finance (opens in a new tab) | Wave Life Sciences LtdCommon Stock | 1.4% | $157M | 26,975,505 | Unchanged | $7.67* | $3.11 | -59.5% |
| 21 | — | Nuvalent Inc-ACommon Stock | 1.3% | $154M | 1,246,456 | Trimmed -50.8% | — | — | — |
| 22 | ABVX on Yahoo Finance (opens in a new tab) | Abivax SA-ADRADR | 1.3% | $151M | 1,132,557 | New | $113.18 | $87.77 | -22.4% |
| 23 | ORKA on Yahoo Finance (opens in a new tab) | Oruka Therapeutics IncCommon Stock | 1.3% | $148M | 1,554,597 | New | $66.63 | $71.01 | +6.6% |
| 24 | CLYM on Yahoo Finance (opens in a new tab) | Climb Bio IncCommon Stock | 1.3% | $147M | 11,300,939 | Unchanged | $4.98* | $9.79 | +96.6% |
| 25 | SLDB on Yahoo Finance (opens in a new tab) | Solid Biosciences IncCommon Stock | 1.0% | $120M | 12,036,126 | Added +28.9% | $5.58* | $5.59 | +0.0% |
| 26 | ZLAB on Yahoo Finance (opens in a new tab) | Zai Lab Ltd-ADRADR | 0.9% | $109M | 5,743,533 | Added +0.6% | $18.54 | $23.64 | +27.5% |
| 27 | SPRY on Yahoo Finance (opens in a new tab) | Ars Pharmaceuticals IncCommon Stock | 0.8% | $87M | 10,860,977 | Unchanged | $6.02* | $3.92 | -34.8% |
| 28 | XNCR on Yahoo Finance (opens in a new tab) | Xencor IncCommon Stock | 0.7% | $85M | 5,274,274 | Added +7.7% | $12.42 | $22.91 | +84.5% |
| 29 | JBIO on Yahoo Finance (opens in a new tab) | Jade Biosciences IncCommon Stock | 0.7% | $82M | 3,671,083 | Unchanged | $17.98 | $13.57 | -24.5% |
| 30 | NTLA on Yahoo Finance (opens in a new tab) | Intellia Therapeutics IncCommon Stock | 0.7% | $77M | 4,526,926 | New | $14.00 | $10.99 | -21.5% |
| 31 | LBRX on Yahoo Finance (opens in a new tab) | Lb Pharmaceuticals IncCommon Stock | 0.6% | $72M | 2,208,604 | Unchanged | $16.18 | $36.47 | +125.4% |
| 32 | DFTX on Yahoo Finance (opens in a new tab) | Definium Therapeutics IncCommon Stock | 0.6% | $71M | 1,500,000 | New | $24.71 | $32.20 | +30.3% |
| 33 | ACRS on Yahoo Finance (opens in a new tab) | Aclaris Therapeutics IncCommon Stock | 0.6% | $67M | 12,723,026 | Added +87.0% | $3.88 | $3.32 | -14.5% |
| 34 | FDMT on Yahoo Finance (opens in a new tab) | 4d Molecular Therapeutics InCommon Stock | 0.6% | $67M | 5,049,779 | Unchanged | $15.51* | $12.28 | -20.8% |
| 35 | SANA on Yahoo Finance (opens in a new tab) | Sana Biotechnology IncCommon Stock | 0.6% | $65M | 18,750,000 | New | $3.22 | $2.30 | -28.6% |
| 36 | DMRA on Yahoo Finance (opens in a new tab) | Damora Therapeutics IncCommon Stock | 0.5% | $62M | 2,399,702 | Unchanged | $25.70 | $18.60 | -27.6% |
| 37 | MNPR on Yahoo Finance (opens in a new tab) | Monopar Therapeutics IncCommon Stock | 0.5% | $62M | 667,207 | Unchanged | $31.96 | $69.54 | +117.6% |
| 38 | ABOS on Yahoo Finance (opens in a new tab) | Acumen Pharmaceuticals IncCommon Stock | 0.5% | $56M | 20,992,669 | Unchanged | $4.38* | $1.70 | -61.3% |
| 39 | GERN on Yahoo Finance (opens in a new tab) | Geron CorpCommon Stock | 0.5% | $55M | 42,809,751 | Trimmed -32.9% | $2.29* | $1.18 | -48.5% |
| 40 | RZLT on Yahoo Finance (opens in a new tab) | Rezolute IncCommon Stock | 0.4% | $49M | 9,445,039 | Added +2.9% | $7.72 | $3.60 | -53.4% |
| 41 | EVMN on Yahoo Finance (opens in a new tab) | Evommune IncCommon Stock | 0.4% | $46M | 3,494,638 | Unchanged | $18.82 | $5.27 | -72.0% |
| 42 | VOR on Yahoo Finance (opens in a new tab) | Vor Biopharma IncCommon Stock | 0.4% | $44M | 2,402,095 | Trimmed -55.6% | $26.54 | $18.25 | -31.3% |
| 43 | IPSC on Yahoo Finance (opens in a new tab) | Century Therapeutics IncCommon Stock | 0.4% | $43M | 17,754,430 | Unchanged | $2.10 | $1.42 | -32.2% |
| 44 | AKTS on Yahoo Finance (opens in a new tab) | Aktis Oncology IncCommon Stock | 0.4% | $42M | 1,314,405 | Trimmed -12.6% | $19.42 | $15.01 | -22.7% |
| 45 | BIOA on Yahoo Finance (opens in a new tab) | Bioage Labs IncCommon Stock | 0.4% | $41M | 1,671,648 | Added +1.3% | $19.24 | $4.94 | -74.3% |
| 46 | CCCC on Yahoo Finance (opens in a new tab) | C4 Therapeutics IncCommon Stock | 0.3% | $37M | 8,000,000 | Unchanged | $2.37 | $2.73 | +15.2% |
| 47 | MIRM on Yahoo Finance (opens in a new tab) | Mirum Pharmaceuticals IncCommon Stock | 0.3% | $37M | 318,554 | Unchanged | $94.07 | $80.24 | -14.7% |
| 48 | CAPR on Yahoo Finance (opens in a new tab) | Capricor Therapeutics IncCommon Stock | 0.3% | $36M | 1,507,844 | Unchanged | $13.06 | $6.73 | -48.5% |
| 49 | PEPG on Yahoo Finance (opens in a new tab) | Pepgen IncCommon Stock | 0.3% | $36M | 20,064,545 | Unchanged | $4.56* | $2.57 | -43.7% |
| 50 | PRLD on Yahoo Finance (opens in a new tab) | Prelude Therapeutics IncCommon Stock | 0.3% | $35M | 6,475,882 | New | $4.35 | $3.26 | -25.1% |
| 51 | NKTX on Yahoo Finance (opens in a new tab) | Nkarta IncCommon Stock | 0.3% | $31M | 10,805,129 | Unchanged | $4.08* | $1.82 | -55.5% |
| 52 | QTTB on Yahoo Finance (opens in a new tab) | Q32 Bio IncCommon Stock | 0.3% | $30M | 2,332,457 | New | $8.36 | $7.40 | -11.4% |
| 53 | AVR on Yahoo Finance (opens in a new tab) | Anteris Technologies GlobalCommon Stock | 0.3% | $30M | 3,000,000 | Unchanged | $5.74 | $6.11 | +6.4% |
| 54 | EDIT on Yahoo Finance (opens in a new tab) | Editas Medicine IncCommon Stock | 0.3% | $29M | 8,889,000 | New | $2.92 | $2.37 | -19.1% |
| 55 | OVID on Yahoo Finance (opens in a new tab) | Ovid Therapeutics IncCommon Stock | 0.2% | $28M | 10,500,968 | Trimmed -2.0% | $1.54 | $2.12 | +38.0% |
| 56 | ASMB on Yahoo Finance (opens in a new tab) | Assembly Biosciences IncCommon Stock | 0.2% | $28M | 1,020,410 | Unchanged | $21.94 | $20.05 | -8.6% |
| 57 | ALXO on Yahoo Finance (opens in a new tab) | Alx Oncology Holdings IncCommon Stock | 0.2% | $27M | 13,011,849 | Unchanged | $1.91 | $1.13 | -40.9% |
| 58 | BNTC on Yahoo Finance (opens in a new tab) | Benitec Biopharma IncCommon Stock | 0.2% | $25M | 1,850,000 | Unchanged | $13.83 | $8.23 | -40.5% |
| 59 | LENZ on Yahoo Finance (opens in a new tab) | Lenz Therapeutics IncCommon Stock | 0.2% | $24M | 4,178,823 | Unchanged | $11.07 | $3.29 | -70.3% |
| 60 | LXEO on Yahoo Finance (opens in a new tab) | Lexeo Therapeutics IncCommon Stock | 0.2% | $23M | 5,000,000 | Unchanged | $9.12 | $2.76 | -69.8% |
| 61 | ACRV on Yahoo Finance (opens in a new tab) | Acrivon Therapeutics IncCommon Stock | 0.2% | $22M | 12,229,396 | Added +46.6% | $6.99* | $1.67 | -76.1% |
| 62 | ALT on Yahoo Finance (opens in a new tab) | Altimmune IncCommon Stock | 0.2% | $20M | 6,500,000 | New | $2.99 | $2.22 | -25.7% |
| 63 | KPTI on Yahoo Finance (opens in a new tab) | Karyopharm Therapeutics IncCommon Stock | 0.2% | $19M | 1,917,354 | Unchanged | $7.62 | $0.34 | -95.6% |
| 64 | DRUG on Yahoo Finance (opens in a new tab) | Bright Minds Biosciences IncCommon Stock | 0.2% | $19M | 265,000 | Unchanged | $80.49 | $51.61 | -35.9% |
| 65 | AVTX on Yahoo Finance (opens in a new tab) | Avalo Therapeutics IncCommon Stock | 0.2% | $18M | 1,000,000 | Added +50.8% | $12.16 | $11.35 | -6.7% |
| 66 | OKUR on Yahoo Finance (opens in a new tab) | Onkure Therapeutics Inc-ACommon Stock | 0.2% | $18M | 3,998,333 | Unchanged | $3.09 | $2.02 | -34.6% |
| 67 | FTH on Yahoo Finance (opens in a new tab) | Faeth Therapeutics IncCommon Stock | 0.2% | $18M | 722,020 | New | $23.13 | $19.01 | -17.8% |
| 68 | AURA on Yahoo Finance (opens in a new tab) | Aura Biosciences IncCommon Stock | 0.2% | $18M | 2,500,000 | New | $7.15 | $6.13 | -14.3% |
| 69 | SABS on Yahoo Finance (opens in a new tab) | Sab Biotherapeutics IncCommon Stock | 0.1% | $17M | 4,401,500 | Unchanged | $2.26 | $2.52 | +11.5% |
| 70 | SPTX on Yahoo Finance (opens in a new tab) | Seaport Therapeutics IncCommon Stock | 0.1% | $15M | 700,000 | New | $17.59 | $17.70 | +0.6% |
| 71 | PALI on Yahoo Finance (opens in a new tab) | Palisade Bio IncCommon Stock | 0.1% | $15M | 7,124,116 | Unchanged | $1.92 | $1.46 | -24.3% |
| 72 | HLXC on Yahoo Finance (opens in a new tab) | Helix Acquisition Corp-Cl ACommon Stock | 0.1% | $13M | 1,250,000 | Unchanged | $10.24 | $10.40 | +1.6% |
| 73 | WAY on Yahoo Finance (opens in a new tab) | Waystar Holding CorpCommon Stock | 0.1% | $11M | 529,400 | Unchanged | $29.02 | $27.57 | -5.0% |
| 74 | EQ on Yahoo Finance (opens in a new tab) | Equillium IncCommon Stock | 0.1% | $10M | 3,096,336 | Unchanged | $1.65 | $1.24 | -24.6% |
| 75 | MGNX on Yahoo Finance (opens in a new tab) | Macrogenics IncCommon Stock | 0.1% | $9M | 1,864,176 | Unchanged | $2.13 | $3.28 | +53.8% |
| 76 | FRNM on Yahoo Finance (opens in a new tab) | Perceptive Capital SolutionsCommon Stock | 0.1% | $8M | 750,000 | Unchanged | $10.07 | $11.83 | +17.4% |
| 77 | ACET on Yahoo Finance (opens in a new tab) | Adicet Bio IncCommon Stock | 0.1% | $8M | 932,624 | Trimmed -21.1% | $10.35 | $4.61 | -55.4% |
| 78 | NAMSW on Yahoo Finance (opens in a new tab) | Newamsterdam Pharma Co NV-27WTS | 0.1% | $7M | 333,333 | Unchanged | $1.84* | $8.82 | +379.3% |
| 79 | CRVS on Yahoo Finance (opens in a new tab) | Corvus Pharmaceuticals IncCommon Stock | 0.1% | $7M | 450,000 | Unchanged | $15.96 | $9.49 | -40.5% |
| 80 | RANI on Yahoo Finance (opens in a new tab) | Rani Therapeutics Holdings-ACommon Stock | 0.1% | $6M | 8,500,000 | Unchanged | $1.51 | $0.64 | -57.6% |
| 81 | JATT on Yahoo Finance (opens in a new tab) | Jatt II Acquisition CorpCommon Stock | 0.0% | $6M | 500,000 | New | $10.63 | $10.25 | -3.6% |
| 82 | AMAN on Yahoo Finance (opens in a new tab) | Amanat Acquisition Corp Cl ACommon Stock | 0.0% | $4M | 375,000 | New | $10.10 | $10.32 | +2.2% |
| 83 | HOWL on Yahoo Finance (opens in a new tab) | Werewolf Therapeutics IncCommon Stock | 0.0% | $859K | 2,387,744 | Trimmed -64.3% | $2.29* | $0.98 | -57.2% |
| 84 | PTN on Yahoo Finance (opens in a new tab) | Palatin Technologies IncCommon Stock | 0.0% | $670K | 62,124 | Trimmed -11.3% | $13.14 | $6.17 | -53.0% |
Sold out since Q1 2026
- —Ascendis Pharma A/S - ADR$2.4B at Q1 2026
- DNTH on Yahoo Finance (opens in a new tab)Dianthus Therapeutics Inc$219M at Q1 2026
- PRAX on Yahoo Finance (opens in a new tab)Praxis Precision Medicines I$120M at Q1 2026
- SRPT on Yahoo Finance (opens in a new tab)Sarepta Therapeutics Inc$85M at Q1 2026
- SYRE on Yahoo Finance (opens in a new tab)Spyre Therapeutics Inc$82M at Q1 2026
- FULC on Yahoo Finance (opens in a new tab)Fulcrum Therapeutics Inc$46M at Q1 2026
- OLMA on Yahoo Finance (opens in a new tab)Olema Pharmaceuticals Inc$39M at Q1 2026
- DSGN on Yahoo Finance (opens in a new tab)Design Therapeutics Inc$32M at Q1 2026
- TVTX on Yahoo Finance (opens in a new tab)Travere Therapeutics Inc$22M at Q1 2026
- GRAL on Yahoo Finance (opens in a new tab)Grail Inc$22M at Q1 2026
- RLMD on Yahoo Finance (opens in a new tab)Relmada Therapeutics Inc$21M at Q1 2026
- STRO on Yahoo Finance (opens in a new tab)Sutro Biopharma Inc$18M at Q1 2026
- CTNM on Yahoo Finance (opens in a new tab)Contineum Therapeutics Inc-A$17M at Q1 2026
- INSP on Yahoo Finance (opens in a new tab)Inspire Medical Systems Inc$17M at Q1 2026
- HNGE on Yahoo Finance (opens in a new tab)Hinge Health Inc-A$14M at Q1 2026
- WGS on Yahoo Finance (opens in a new tab)Genedx Holdings Corp$13M at Q1 2026
- RNA on Yahoo Finance (opens in a new tab)Atrium Therapeutics Inc$12M at Q1 2026
- MPLT on Yahoo Finance (opens in a new tab)Maplight Therapeutics Inc$5M at Q1 2026
Estimated, from reported holdings
Quarter by quarter
High-conviction buys (new positions at 3% or more of the portfolio) since Q3 2023: 2. Of 0 with six months of history, — beat the S&P 500 from the filing date.
Source: SEC Form 13F-HR 0001104659-26-097251, compared with the Q1 2026 report. 0 option rows are excluded from weights. Tickers map from CUSIP via OpenFIGI. Estimated returns weight each position’s next-quarter total return (Yahoo Finance adjusted closes) by its quarter-end value and assume no trades. Estimated cost averages daily adjusted closes in each quarter the share count rose, from Q3 2023 onward (* = held at the start of our data). Price is the latest close.
Important information
Form 13F data is delayed. Managers have up to 45 days after each calendar quarter to file, so holdings shown may have changed materially since the report date. 13F reports cover long positions in US-listed equities and certain other securities only; they exclude short positions, most non-US holdings, cash, bonds and private investments, and managers may request confidential treatment for some positions. Options rows are listed in filings but are not counted in the holdings and weights shown here.
Estimated holdings returns, estimated cost and high-conviction results are hypothetical calculations from quarter-end holdings and public prices, assuming no trades between reports. They are not the actual returns or costs of any fund or manager and do not reflect fees, trading, leverage, shorts or cash. Biographies are drawn from cited public sources. This page is for information only and is not individualized investment advice or a recommendation to buy or sell any security. Gulfstream Capital and its clients may hold positions in securities shown.